Sandoz Will Appeal Against US Enbrel Patent Setback
• By Aidan Fry
Sandoz could be barred from launching its Erelzi biosimilar etanercept in the US until 2029 following an adverse district court ruling • Source: Shutterstock
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
